Middle East Live

Contacts

Queries to:
Samuel JK Abraham
info@gncorporation.com

Permalink : https://www.aetoswire.com/news/researcher-john-craig-venter-is-awarded-the-2020-edogawa-niche-prize-for-his-accomplishment-in-human-genome-research/en

SAN FRANCISCO-Tuesday 11 August 2020 [ AETOS Wire ]

(BUSINESS WIRE) -- Visa (NYSE: V), a leading global payments technology company, today announced that yesterday it successfully priced its inaugural green bond offering, totaling $500 million, paying a semi-annual coupon of 0.75% and maturing August 15, 2027. The green bond, believed to be the first issued by a digital payments network, will be used to help advance the company’s commitment to environmental sustainability and a sustainable payments ecosystem. In support of that commitment and in addition to its inaugural green bond, Visa is also announcing the appointment of its first chief sustainability officer, Douglas Sabo.

“At Visa, we see a responsibility and an opportunity to use the power of our network to drive broad shifts toward a sustainable future,” said Al Kelly, chairman and chief executive officer of Visa Inc. “Our green bond offering will help us accelerate the transformation of our infrastructure and operations to reach our environmental goals. This commitment extends to appointing Visa’s first chief sustainability officer, tasked with ensuring we continue to take bold and industry-leading actions on the environment.”

As outlined in the Visa Green Bond Framework, the proceeds of the green bond will be used to fund projects including upgrades to buildings, energy efficiency improvements, expanded usage of renewable energy sources, water efficiency projects, employee commuter programs, and research and initiatives focused on sustainable consumer behaviors. The proceeds also will support investments in projects to inspire and foster sustainable living in support of the United Nations Sustainable Development Goals. These projects build on Visa’s sustainability leadership, including its transition to 100 percent renewable electricity across its operations achieved at the start of 2020.

“As the world continues to address the urgency of climate change and other environmental challenges, we are embracing our opportunity to play a leading role in building a more sustainable world,” said Douglas Sabo, Visa’s newly appointed chief sustainability officer. “Through our green bond offering and together with our initiatives driving inclusive economic growth, we are working to ensure people and planet both can thrive together.”

Visa will issue an annual report on the use of proceeds from the green bond and their environmental impact. Sustainalytics, a leading global provider of ESG research, ratings and data, provided the second-party opinion on the environmental benefits of Visa’s Green Bond Framework as well as its alignment with the Green Bond Principles.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that relate to, among other things, our sustainability goals, current and future projects, and expectations regarding the use of proceeds. Forward-looking statements generally are identified by words such as “believes,” “estimates,” “expects,” “intends,” “may,” “could,” “should,” “will,” “continue” and other similar expressions. All statements other than statements of historical fact could be forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance and are subject to certain risks, uncertainties and other factors, many of which are beyond our control and are difficult to predict. We describe risks and uncertainties that could cause actual results to differ materially from those expressed in, or implied by, any of these forward-looking statements in our SEC filings, including our Annual Report on Form 10-K for the year ended September 30, 2019 and our subsequent reports on Forms 10-Q and 8-K, which are incorporated by reference herein. Except as required by law, we do not intend to update or revise any forward-looking statements as a result of new information, future events or otherwise.

About Visa Inc.

Visa is the world’s leader in digital payments. Our mission is to connect the world through the most innovative, reliable and secure payment network – enabling individuals, businesses and economies to thrive. Our advanced global processing network, VisaNet, provides secure and reliable payments around the world, and is capable of handling more than 65,000 transaction messages a second. The company’s relentless focus on innovation is a catalyst for the rapid growth of connected commerce on any device. As the world moves from analogue to digital, Visa is applying our brand, products, people, network and scale to reshape the future of commerce. For more information visit usa.visa.com/about-visa.html, usa.visa.com/visa-everywhere/blog.html and @VisaNews.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200811005278/en/

Contacts

Lindy Mockovak
lindy.mockovak@visa.com

Permalink : https://www.aetoswire.com/news/visa-expands-commitment-to-sustainability-through-inaugural-500-million-green-bond-issuance-and-appointment-of-chief-sustainability-officer-role/en 

Contacts

Ms Li Huimin
Email: hisun-haisheng@hisunpharm.com

Permalink : https://www.aetoswire.com/news/hisunrsquos-favipiravir-continuously-supports-the-middle-eastrsquos-endeavor-in-fighting-covid-19/en

 • Novavax will license COVID-19 vaccine technology to Takeda for local production and commercialization in Japan

• Matrix-M adjuvant to be supplied from Novavax

• Government of Japan will provide funding to Takeda for technology transfer, establishment of infrastructure and scale-up of manufacturing

• Adds to Takeda’s ongoing support of influenza pandemic preparedness in Japan

GAITHERSBURG, Md. & OSAKA, Japan-Saturday 8 August 2020 [ AETOS Wire ]

(BUSINESS WIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), today announced a partnership for the development, manufacturing and commercialization of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate, in Japan. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ recombinant protein nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant. Takeda will receive funding from the Government of Japan’s Ministry of Health, Labour and Welfare (MHLW) to support the technology transfer, establishment of infrastructure and scale-up of manufacturing. Takeda anticipates the capacity to manufacture over 250 million doses of the COVID-19 vaccine per year1.

“Takeda’s leading position in Japan, technical expertise, regulatory know-how and manufacturing capacity make the company an ideal partner to further expand the global availability of NVX‑CoV2373,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “We look forward to collaborating with Takeda to rapidly develop, produce and commercialize the vaccine in Japan.”

Novavax and Takeda are partnering on manufacturing, clinical development and regulatory activities in Japan. Novavax will license and transfer manufacturing technologies to enable Takeda to manufacture the vaccine antigen and will supply the Matrix-M adjuvant to Takeda. Takeda will be responsible for regulatory submission to the MHLW and will produce and distribute NVX‑CoV2373 in Japan.

“Nothing is more important right now than protecting the world against COVID-19. We are excited to collaborate with Novavax to bring their promising vaccine candidate to Japan,” said Rajeev Venkayya, M.D., President of the Global Vaccine Business Unit, Takeda. “Today’s announcement builds upon our ongoing support of pandemic preparedness and demonstrates Takeda’s commitment to the health and well-being of the Japanese population.”

Novavax will be entitled to receive payments based on the achievement of certain development and commercial milestones, as well as a portion of proceeds from the vaccine.

About NVX-CoV2373

NVX‑CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS‑CoV‑2, the virus that causes COVID-19 disease. NVX‑CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax’ patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. In preclinical trials, NVX‑CoV2373 demonstrated indication of antibodies that block binding of spike protein to receptors targeted by the virus, a critical aspect for effective vaccine protection. In its Phase 1 data of the Phase 1/2 clinical trial, NVX‑CoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera. Novavax was awarded $1.6 billion by the federal government as part of Operation Warp Speed (OWS), a U.S. government program to deliver millions of doses of a safe, effective vaccine for COVID-19 to the U.S. population. The OWS funding is being used by Novavax to complete late-stage clinical development, including a pivotal Phase 3 clinical trial; establish large-scale manufacturing; and deliver 100 million doses of NVX‑CoV2373 beginning as early as late 2020. The Coalition for Epidemic Preparedness Innovations (CEPI) is also investing up to $388 million, and Department of Defense (DoD) is investing up to $60 million of funding to advance clinical development of NVX‑CoV2373.

About Matrix-M™

Novavax’ patented saponin-based Matrix-M™ adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax is undergoing clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NVX‑CoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera in its Phase 1 data of the Phase 1/2 clinical trial. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit https://www.takeda.com.

Takeda’s Commitment to Vaccines

Vaccines prevent 2 to 3 million deaths each year and have transformed global public health. For the past 70 years, Takeda has supplied vaccines to protect the health of people in Japan. Today, Takeda’s global vaccine business is applying innovation to tackle some of the world’s most challenging infectious diseases, such as dengue, Zika and norovirus. Takeda’s team brings an outstanding track record and a wealth of knowledge in vaccine development, manufacturing and global access to advance a pipeline of vaccines to address some of the world’s most pressing public health needs. For more information, visit www.TakedaVaccines.com.

Novavax Forward-Looking Statements

Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products, including statements regarding the rights and responsibilities of each of Novavax and Takeda in their partnership, plans related to manufacturing [(including vaccine antigen dose amounts)], development, regulatory and commercial activities in Japan, potential payments to Novavax from Takeda, Novavax’ expectations of third-party funding and anticipated timing of Novavax’ clinical trial results are forward-looking statements. These statements may be identified by words such as “expect,” “look forward,” “potential,” “will” and similar references to future periods. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include uncertainty of success in the development and potential commercialization of NVX-CoV2373, unexpected delays in clinical trials or regulatory review of NVX-CoV2373, potential set backs in scaling up manufacturing of NVX-CoV2373, adverse impacts of the ongoing COVID-19 pandemic on Novavax’ business, Novavax’ future capital requirements and availability of funding, as well as those risks identified under the heading “Risk Factors” in the Novavax Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission (SEC), and updated by any Quarterly Report on Form 10-Q, particularly the risks inherent to developing novel vaccines. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements.

Takeda Pharmaceutical Company Limited Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

_________________________

1.
    

The projected capacity is an estimate only based on current assumptions from Novavax.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200807005160/en/

Contacts

Novavax

Investors
Silvia Taylor and Erika Trahan
ir@novavax.com
240-268-2022

Media
Brandzone/KOGS Communication
Edna Kaplan
kaplan@kogspr.com
617-974-8659

Takeda Pharmaceuticals

Media in Japan
Kazumi Kobayashi
+81 (0) 3-3278-2095
kazumi.kobayashi@takeda.com

Media Outside Japan
Amy Atwood
+1 774-571-3316
amy.atwood@takeda.com

Permalink : https://www.aetoswire.com/news/novavax-and-takeda-announce-collaboration-for-novavaxrsquo-covid-19-vaccine-candidate-in-japan/en

 One year since the Fusarium Wilt Tropical Race 4 (TR4) presence was confirmed in Latin America, produce leader broadly exploring all available solutions to ensure bananas endure and remain a food staple across the globe.

CHARLOTTE, N.C.-Monday 3 August 2020 [ AETOS Wire ]

(BUSINESS WIRE)-- Dole Food Company today shared the company’s most recent update on its efforts to combat Fusarium Tropical Race 4 (TR4), a plant disease that poses an existential threat to bananas, a major staple crop for much of the world.

Since the discovery of TR4 in northern Colombia one year ago, Dole swiftly ramped-up its TR4 response plan, implementing site-specific TR4 prevention activities throughout Latin America in coordination with local authorities and international experts to contain and prevent spread.

A three-year containment program was immediately implemented in 2019 to ensure biosecurity protocols in every Dole banana farm, as well as those of Dole’s independent suppliers. Those protocols build upon best practices implemented in the banana producing countries where the disease has been successfully contained and are continually reviewed and strengthened per site—based upon the farm layout and location—to maximize the effectiveness of the risk-based mitigation plan.

Dole also continues to share these best practices with independent growers and to engage with governments, multi-stakeholder initiatives and industry partners to ensure that our actions are coordinated with the wider response, both in Latin America and globally. These efforts require significant investment and as of now there is no evidence that TR4 has spread from the area in Colombia in which it was initially detected.

“Fortunately to date, the spread of this disease in Latin America has been contained to only the La Guajira region of Colombia, but this issue is not isolated to one region or one banana grower; it affects the entire industry and we must all be vigilant,” stated Patricio Gutiérrez, Director of Innovation R&D, Dole Tropical Products. “Containment alone is not sufficient. We must find ways to move beyond defense and find a sustainable solution to this issue in the long-term.”

Dole is exploring a number of potential resolutions.

One such solution the company is investigating is how to implement safe and approved biological control measures to prevent disease.

Additionally, Dole is working closely with research institutions around the world toward developing a disease resistant banana variety through crop improvement and conventional breeding methods. Since 2016, Dole has participated in a consortium working in partnership with the Honduran Research Foundation (FHIA) on the development of banana varieties that are resistant to TR4. Although developing a new kind of banana through traditional breeding is painstaking work, the research team is making good progress and a number of lines are currently being pot or field tested for TR4 resistance.

More recently, Dole began collaborating with companies working on precision biotechnology as a means to develop TR4 resistant bananas and is also part of the Global Alliance against TR4 led by IICA and Bayer in collaboration with other large banana stakeholders. When and if either these efforts or the other work being done by third parties succeed, Dole intends to be part of the discussion on how to make the solution available to banana growers worldwide.

About Dole Food Company

Dole Food Company, Inc., is one of the world’s largest producers and marketers of high-quality fresh fruit and fresh vegetables. Dole is an industry leader in many of the products it sells, as well as in nutrition education. For more information, please visit www.dole.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200731005419/en/

Contacts

US Contact: William Goldfield
818-874-4647
william.goldfield@dole.com

Permalink : https://www.aetoswire.com/news/dole-unveils-integrated-strategy-against-banana-disease/en

Follow-on investment to accelerate Sintavia’s growth plans in key Aerospace and Space markets 

NEW YORK -Wednesday 5 August 2020 [ AETOS Wire ]

(BUSINESS WIRE)-- Sumitomo Corporation of Americas (“SCOA”), the largest subsidiary of Sumitomo Corporation, one of the world’s largest traders of goods and services, announced today that it entered into an agreement to increase its investment in Sintavia, LLC (“Sintavia”), the Aerospace and Space industry’s leading Tier One metal additive manufacturer, based in Hollywood, FL. The parties jointly announced that the minority investment, which follows an initial investment by SCOA in 2018, will be used to fund Sintavia’s rapidly growing business of providing additively manufactured parts to the world’s largest Aerospace and Space companies. Terms of the deal were not disclosed.

The investment will help Sintavia scale its production capacity for flight-critical components that are produced via additive manufacturing while continuing to advance its industry-leading technical capabilities. In addition to the financial investment, SCOA and Sintavia will continue to identify opportunities to apply Sintavia’s best-in-class additive manufacturing and design capabilities toward Sumitomo Corporation Group’s global industrial activities.

“We truly value SCOA as a long-term partner for Sintavia and are excited to expand our existing relationship. With this investment, we are further aligning ourselves with a global thought leader in additive manufacturing that is committed to supporting our continued growth,” said Brian R. Neff, Sintavia’s Chief Executive Officer and Managing Partner of Neff Capital Management LLC, Sintavia’s majority owner.

“Since our initial investment in 2018, we’ve been impressed by Sintavia’s leadership and growth in such a short time,” said Kevin Hyuga, SVP and General Manager of SCOA’s Construction and Transportation Systems Group. “We see continued synergies in the future through this partnership, and look forward to continuing to help Sintavia support the Aerospace and Space industry. Moreover, Sintavia is well-aligned with our company’s sustainability goals. Through its technology, Sintavia is capable of reducing waste in the additive manufacturing production process, allowing end-stage products to fly lighter, ultimately reducing greenhouse gases and helping to create a more sustainable society.”

The transaction is expected to close in the second half of 2020 following customary regulatory review. RBC Capital Markets acted as exclusive advisor to Sintavia on the transaction.

About Sumitomo Corporation of Americas

Established in 1952 and headquartered in New York City, Sumitomo Corporation of Americas (SCOA) has eight offices in major U.S. cities. SCOA is the largest subsidiary of Sumitomo Corporation, one of the world’s leading traders of goods and services. As an integrated business enterprise, the firm has emerged as a major organizer of multinational projects, an expediter of ideas, an important international investor and financier, and a powerful force for distribution of products and global communications through a network of offices worldwide. Its core business units include Tubular Products, Environment and Infrastructure, Steel and Non Ferrous Metals, Transportation and Construction Systems, Chemicals and Electronics, Media and IOT Applications, Real Estate, Mineral Resources and Energy, and Food. For more information, visit www.sumitomocorp.com.

About Sintavia

Sintavia is the global leader in applied additive manufacturing for the Aerospace and Space industry. With high-speed printers co-located alongside precision post processing equipment, a full complement of mechanical testing equipment, and a full metallurgical and powder laboratory, Sintavia is able to optimize parameters, serially manufacture, and audit quality parts for aerospace applications. A founding member of the Additive Manufacturer Green Trade Association, Sintavia is committed to the highest quality standards in the industry, and holds multiple Nadcap and other aerospace accreditations. For more information visit http://www.sintavia.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200804005311/en/

Contacts

Lindsay Lewis, Sintavia
+1 954.474.7800

Jewelle Yamada, Sumitomo Corporation of Americas
+1 212.207.0574

Amy Babcock, Sumitomo Corporation of Americas
+1 212.207.0567

Permalink : https://www.aetoswire.com/news/sumitomo-corporation-of-americas-makes-strategic-investment-in-sintavia-1/en 

 ‘The End of Football’ is Manchester City and Xylem’s latest effort to educate one billion people globally about urgent water challenges

RYE BROOK, N.Y-Wednesday 29 July 2020 [ AETOS Wire ]

(BUSINESS WIRE)-- Manchester City stars Sergio Agüero, Phil Foden and Raheem Sterling all feature in an emotive new short film that aims to bring home the reality of the global water crisis to football fans across the world. Released on World Conservation Day, ‘The End of Football’ is the latest campaign by global water technology company, Xylem (NYSE:XYL) and Manchester City, to drive awareness of escalating water challenges among the Club’s huge fan base.

For many football fans the reality of living with extreme water scarcity is now just one generation away. The latest UN data estimates that almost 5 billion people globally could be living in areas of water scarcity by 20501. The UK Environmental Protection Agency forecasts that, due to mounting pressures such as increased demand, aging infrastructure and climate change, parts of England could run out of water by 2045 – a warning echoed in a recent UK Public Accounts Committee report on the country’s water supplies2.

The End of Football film, featuring multiple Manchester City footballers, aims to capture the imagination of football fans by depicting a world without water. Filmed in the Club’s iconic Etihad Stadium, the video highlights the detrimental impact that water complacency can have on society, including football, as it tracks one girl’s journey as a Manchester City fan.

Patrick Decker, Xylem President and Chief Executive Officer, said: “Water sits at the heart of human health and the sustainability of our planet. Through our partnership with City Football Group, we’re focused on mobilizing the global community to actively join us in safeguarding this precious resource. Together, we have a powerful opportunity to turn the tide on challenges like water scarcity and flooding and build a water-secure future.”

Pete Bradshaw, Head of Sustainability at Manchester City, said: “Xylem is doing incredible work to address water sustainability issues and Manchester City is proud to support them in this new campaign.”

Joseph Vesey, Senior Vice President and Chief Marketing Officer at Xylem, added: “Though the End of Football campaign was conceived and shot before the coronavirus pandemic brought a temporary halt to football, the message behind the campaign has never been more appropriate. With the support of the Club and its legions of fans, we have the power to elevate the conversation on water conservation and create a more sustainable future for all.”

Fans can learn more about water conservation through the Manchester City ‘Water Hero Playbook’, which contains simple, everyday actions on saving water – along with advice from public officials and industry – to protect our future and the future of football.

As part of its multi-year partnership with Manchester City, Xylem has partnered with the Club to deliver clean water towers, WASH education, and sports and leadership training to communities around the world. In less than two years, the partnership has already directly provided access to clean water and WASH education to over 10,000 children across India, Thailand, China, Australia and the United States.

Global sports marketing agency SPORTFIVE and its creative agency partner Brave developed and produced the End of Football campaign. As Xylem’s retained agency, SPORTFIVE has been helping the global water technology company and Manchester City FC to raise awareness of water complacency since 2018.

About Xylem

Xylem (XYL) is a leading global water technology company committed to developing innovative technology solutions to the world’s water challenges. The Company’s products and services move, treat, analyze, monitor and return water to the environment in public utility, industrial, residential and commercial building services settings. Xylem also provides a leading portfolio of smart metering, network technologies and advanced infrastructure analytics solutions for water, electric and gas utilities. The Company’s more than 16,000 employees bring broad applications expertise with a strong focus on identifying comprehensive, sustainable solutions. Headquartered in Rye Brook, New York, with 2019 revenue of $5.25 billion, Xylem does business in more than 150 countries through a number of market-leading product brands. For more information, please visit us at www.xylem.com.

About Xylem Watermark

Xylem Watermark, the company’s corporate citizenship program, was initiated in 2008, with a focus on protecting and providing safe water resources for communities around the world and also educating people on water related issues. In 2016, Xylem Watermark launched a three-year program focusing on employee volunteerism globally to drive rapid growth in employee engagement in providing social value within our communities.

About Manchester City Football Club

Manchester City FC is an English Premier League club initially founded in 1880 as St Mark’s West Gorton. It officially became Manchester City FC in 1894 and has since then gone onto win the European Cup Winners’ Cup, six League Championship titles, including four Premier League titles (2012, 2014, 2018, 2019), and six FA Cups. Manchester City FC is one of nine clubs comprising the City Football Group and counts New York City FC and Melbourne City FC among its sister clubs.

Under manager Pep Guardiola, one of the most highly decorated managers in world football, the Club plays its domestic and UEFA Champions League home fixtures at the Etihad Stadium, a spectacular 55,000 seat arena that City have called home since 2003. Today, the Stadium sits on the wider Etihad Campus, which also encompasses the City Football Academy, a state-of-the-art performance training and youth development facility located in the heart of East Manchester. Featuring a 7,000 capacity Academy Stadium, the City Football Academy is also where Manchester City Women’s Football Club and the Elite Development Squad train on a daily basis and play their competitive home games.

For more information, please visit www.mancity.com

About SPORTFIVE

SPORTFIVE is a global partnership marketing agency fuelled by the expertise, experience and privileged access of a global leader in sports, entertainment, media and lifestyle.

We help brands engage with their audiences and fans through partnerships, as we believe that partnering with things that people truly care about is the best way for brands to remain relevant and impactful.

About Brave

Brave is an award-winning creative agency that de-risks commercial decision-making by being creatively courageous, strategically forensic, digitally progressive, data smart and behaviour driven. We make progressive ideas feel safe – through a belief that creativity and data have a complementary relationship. We pioneered the use of biometrics through the development of our proprietary ‘Bravery Index’ tool. This has helped us optimise our work ever since, by letting us emotionally test, qualify and validate our campaigns for a greater chance of enjoying commercial success.

In 2017 Brave was acquired by SPORTFIVE , which provides a global footprint and access to the world’s most sought-after rights holders, talent, OTT (streaming) platforms/broadcasters and brands. Brave have taken the stage at prestigious events all over the world including; Cannes Lions, Advertising Week, IAB Engage, Eurobest and Dubai Lynx. For more information, find us at Brave.co.uk.

__________________
1 https://www.wateraid.org/uk/media/un-warns-around-5-billion-people-could-face-water-shortages-by-2050-wateraid-response
2 https://www.nao.org.uk/press-release/water-supply-and-demand-management/

View source version on businesswire.com: https://www.businesswire.com/news/home/20200728005532/en/

Contacts

Houston Spencer
+1 (914) 240-3046
Houston.Spencer@xyleminc.com

Olivia Dempsey
+353 (0) 85 118-2288
Olivia.Dempsey@edelman.com

Permalink : https://www.aetoswire.com/news/manchester-cityrsquos-aguumlero-foden-sterling-and-others-feature-in-new-film-highlighting-the-growing-threat-of-global-water-shortages/en

NEW YORK-Monday 3 August 2020 [ AETOS Wire ]

(BUSINESS WIRE) -- For the second straight year, Moody’s Analytics has won the Risk Technology Awards for IFRS 9 – Enterprise Solution of the Year and IFRS 9 – ECL Modelling Solution of the Year. The two IFRS 9 awards bring the Moody’s Analytics tally to seven in the 2020 Risk Technology Awards program.

The complexity introduced into financial reporting by the IFRS 9 accounting standard has proven to be a major challenge. Measuring and reporting on the future performance of credit portfolios has introduced new data, analytics, and financial processes. Moody’s Analytics solutions for IFRS 9 are modular and flexible, to help institutions of any size meet the standard while strengthening their risk management and decision-making processes.

The ImpairmentStudio™ for IFRS 9 platform is central to our IFRS 9 offering. This cloud-based software lets customers automate their impairment analysis while managing and monitoring their expected credit losses efficiently. The solution encompasses our award-winning economic forecasts, scenarios, data, and models.

“We’re honored to win these two awards again,” said Cris deRitis, Deputy Chief Economist at Moody’s Analytics. “The upheaval caused by COVID-19 reminds us that the expected credit losses that must be calculated for IFRS 9 can change quickly and dramatically, given the varying paths the economy can take. It also underscores the importance of using flexible impairment tools with credible forecasts for effective risk management. These awards are a testament to our market-leading capabilities.”

The Risk Technology Awards recognize outstanding vendors helping the industry in the fields of ALM, credit, operational risk, and enterprise risk management.

This win adds to the growing list of awards and industry accolades for Moody’s Analytics.

About Moody’s Analytics

Moody’s Analytics provides financial intelligence and analytical tools to help business leaders make better, faster decisions. Our deep risk expertise, expansive information resources, and innovative application of technology help our clients confidently navigate an evolving marketplace. We are known for our industry-leading and award-winning solutions, made up of research, data, software, and professional services, assembled to deliver a seamless customer experience. We create confidence in thousands of organizations worldwide, with our commitment to excellence, open mindset approach, and focus on meeting customer needs. For more information about Moody’s Analytics, visit our website or connect with us on Twitter and LinkedIn.

Moody's Analytics, Inc. is a subsidiary of Moody's Corporation (NYSE: MCO). Moody’s Corporation reported revenue of $4.8 billion in 2019, employs approximately 11,300 people worldwide and maintains a presence in 40 countries.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200803005207/en/

Contacts

JUSTIN BURSZTEIN
Moody’s Analytics Communications
+1.212.553.1163
justin.bursztein@moodys.com

Moody’s Analytics Media Relations

moodysanalytics.com
twitter.com/moodysanalytics
linkedin.com/company/moodysanalytics

Permalink : https://www.aetoswire.com/news/moodyrsquos-analytics-repeats-ifrs-9-wins-at-risk-technology-awards/en